These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 22365729)
1. p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD. Banerjee A; Koziol-White C; Panettieri R Curr Opin Pharmacol; 2012 Jun; 12(3):287-92. PubMed ID: 22365729 [TBL] [Abstract][Full Text] [Related]
2. Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies. Pelaia C; Vatrella A; Gallelli L; Lombardo N; Sciacqua A; Savino R; Pelaia G Drug Des Devel Ther; 2021; 15():1275-1284. PubMed ID: 33790539 [TBL] [Abstract][Full Text] [Related]
3. Tristetraprolin and its role in regulation of airway inflammation. Prabhala P; Ammit AJ Mol Pharmacol; 2015 Apr; 87(4):629-38. PubMed ID: 25429052 [TBL] [Abstract][Full Text] [Related]
4. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. Knobloch J; Sibbing B; Jungck D; Lin Y; Urban K; Stoelben E; Strauch J; Koch A J Pharmacol Exp Ther; 2010 Dec; 335(3):788-98. PubMed ID: 20801891 [TBL] [Abstract][Full Text] [Related]
5. Upregulation of RGS4 expression by IL-1beta in colonic smooth muscle is enhanced by ERK1/2 and p38 MAPK and inhibited by the PI3K/Akt/GSK3beta pathway. Hu W; Li F; Mahavadi S; Murthy KS Am J Physiol Cell Physiol; 2009 Jun; 296(6):C1310-20. PubMed ID: 19369446 [TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor. Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108 [TBL] [Abstract][Full Text] [Related]
7. Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Catley MC; Sukkar MB; Chung KF; Jaffee B; Liao SM; Coyle AJ; Haddad el-B; Barnes PJ; Newton R Mol Pharmacol; 2006 Aug; 70(2):697-705. PubMed ID: 16687566 [TBL] [Abstract][Full Text] [Related]
8. Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells. Higham A; Karur P; Jackson N; Cunoosamy DM; Jansson P; Singh D Int J Chron Obstruct Pulmon Dis; 2018; 13():1279-1288. PubMed ID: 29719383 [TBL] [Abstract][Full Text] [Related]
9. Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. Munoz L; Ramsay EE; Manetsch M; Ge Q; Peifer C; Laufer S; Ammit AJ Eur J Pharmacol; 2010 Jun; 635(1-3):212-8. PubMed ID: 20226180 [TBL] [Abstract][Full Text] [Related]
10. Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone. Raidl M; Sibbing B; Strauch J; Müller K; Nemat A; Schneider PM; Hag H; Erdmann E; Koch A Cell Biochem Biophys; 2007; 49(2):98-110. PubMed ID: 17906365 [TBL] [Abstract][Full Text] [Related]
11. [The action of p38 MAP kinase and its inhibitors on endometriosis]. Zhou WD; Chen QH; Chen QX Yao Xue Xue Bao; 2010 May; 45(5):548-54. PubMed ID: 20931753 [TBL] [Abstract][Full Text] [Related]
12. In vitro modeling of COPD inflammation and limitation of p38 inhibitor - SB203580. Meng A; Zhang X; Wu S; Wu M; Li J; Yan X; Kopec-Harding K; Wu J Int J Chron Obstruct Pulmon Dis; 2016; 11():909-17. PubMed ID: 27199554 [TBL] [Abstract][Full Text] [Related]
14. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy. Johansen C; Vinter H; Soegaard-Madsen L; Olsen LR; Steiniche T; Iversen L; Kragballe K Br J Dermatol; 2010 Dec; 163(6):1194-204. PubMed ID: 20846304 [TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. Singh D; Smyth L; Borrill Z; Sweeney L; Tal-Singer R J Clin Pharmacol; 2010 Jan; 50(1):94-100. PubMed ID: 19880675 [TBL] [Abstract][Full Text] [Related]
16. Bronchial epithelial cells produce CXCL1 in response to LPS and TNFα: A potential role in the pathogenesis of COPD. Inui T; Watanabe M; Nakamoto K; Sada M; Hirata A; Nakamura M; Honda K; Ogawa Y; Takata S; Yokoyama T; Saraya T; Kurai D; Wada H; Ishii H; Takizawa H Exp Lung Res; 2018 Sep; 44(7):323-331. PubMed ID: 30676127 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504). Kent LM; Smyth LJ; Plumb J; Clayton CL; Fox SM; Ray DW; Farrow SN; Singh D J Pharmacol Exp Ther; 2009 Feb; 328(2):458-68. PubMed ID: 19004925 [TBL] [Abstract][Full Text] [Related]
18. p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration. Studer RK; Aboka AM; Gilbertson LG; Georgescu H; Sowa G; Vo N; Kang JD Spine (Phila Pa 1976); 2007 Dec; 32(25):2827-33. PubMed ID: 18246004 [TBL] [Abstract][Full Text] [Related]
19. Progress towards the development of anti-inflammatory inhibitors of IKKbeta. Bamborough P; Callahan JF; Christopher JA; Kerns JK; Liddle J; Miller DD; Morse MA; Rumsey WL; Williamson R Curr Top Med Chem; 2009; 9(7):623-39. PubMed ID: 19689370 [TBL] [Abstract][Full Text] [Related]
20. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD. Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]